Abstract decorative geometric graphic used as a design element.

Join us at ASCO 2026

Prosigna Breast Risk of Recurrence Test

Booth 13069

Featured Presentation

First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer

Saturday, May 30th | 1:15 PM CDT
Breast Cancer – Local/Regional/Adjuvant, Hall B1

Robert C. Stein, Ph.D., MBBChir, FRCP
University College London, OPTIMA trial Chief Investigator

Learn More

You’re invited to a dinner program

New treatment guidance for high-risk breast cancer patients

Sunday, May 31 | 6:30 PM CDT
Harry Caray’s Italian Steakhouse – River North

RSVP Now

Co-Chief Investigator Prof. Iain Macpherson will present results from OPTIMA1 a phase III randomized non‑inferiority trial evaluating test‑directed chemotherapy in patients with high clinical risk, ER‑positive early breast cancer.

A panel discussion will follow, exploring the potential impact of these findings on future treatment decisions for high‑risk patients.

Prof. Iain Macpherson headshot

Presenter
Prof. Iain Macpherson

University of Glasgow

Prof. Matthew Ellis headshot

Panelist
Prof. Matthew Ellis

State University of Campinas

Dr. Tari King headshot

Panelist
Dr. Tari King

Emory University

Prof. Stuart McIntosh headshot

Panelist
Prof. Stuart McIntosh

Queen’s University Belfast

Dr. Charles Perou headshot

Panelist
Dr. Charles Perou

Lineberger Cancer Center, UNC

Dr. Kelly Marcom headshot

Moderator
Dr. Kelly Marcom

Veracyte, Inc.

Prof. Iain Macpherson headshot

Presenter
Prof. Iain Macpherson

University of Glasgow

Prof. Matthew Ellis headshot

Panelist
Prof. Matthew Ellis

State University of Campinas

Dr. Tari King headshot

Panelist
Dr. Tari King

Emory University

Prof. Stuart McIntosh headshot

Panelist
Prof. Stuart McIntosh

Queen’s University Belfast

Dr. Charles Perou headshot

Panelist
Dr. Charles Perou

Lineberger Cancer Center, UNC

Dr. Kelly Marcom headshot

Moderator
Dr. Kelly Marcom

Veracyte, Inc.

Explore Prosigna

Biomarker Testing for Early-Stage Breast Cancer

Learn more

Scientific Publications

Prosigna publications and references showcasing breast cancer discoveries and advancements.

Explore

Fighting Breast Cancer with Genomic Testing

Learn More

Prosigna Resource Center

View scientific publications, videos, FAQS, and more.

Explore

Connect with us

Meet With Our Team

References

  1. https://optimabreaststudy.com/

Disclaimers

The Prosigna Breast Cancer Prognostic Gene Signature Assay is available as a CE-IVD test outside the US. To find out if Prosigna is available in your country or for information about reimbursement and insurance coverage, contact us at [email protected].

Talk to your doctor about whether Veracyte tests might be right for you.